Bringing Objective Measurement to Behavioral Health
Future Life is developing Face2Face™ a software platform for advanced mental health evaluation and treatment.
Face2Face™ combines telehealth, microexpression detection, and speech to text into one convenient platform. A neural network model of this data is used to more accurately assess mental health.
Mental & Behavioral Health Applications
In addition to PTSD and other traumas (sexual assault, urban trauma, first response), there are a wide range of applications that Face2Face™ has the potential to address.
The future Face2Face™ product portfolio will include, but are not limited to:
•Face2Face™ Public Safety/Homeland Security: Criminal Investigation and Intelligence
•Face2Face™ Human Capital: Recruitment, Personnel Management, Organizational Development
•Face2Face™ Education: IEPs and Learning Disability, Autism Spectrum Disorders, Conduct Disorders
•Face2Face™ Recovery: Early Recovery from Substance Abuse. Identify those at high risk of relapse to trigger additional care
Future Life Clinical Roadmap
Clinical Trials and Proof-of-Concept Studies
Academic Studies with American University, Department of Psychology, Emotions Lab
Study #1: Initiated February 2018 and ongoing.Evaluation of Emotional Reactivity and Accuracy of Emotional Responses to Standardized Interpersonal Stimuli in Patients with Borderline Personality Disorder using the Face2Face™ emotional analysis system.
─ Interpersonal Emotion Lab with Dr. Nathaniel Herr
Study #2: Starting August 2018. Measuring the Impact of Sleep Deprivation as an Analog for Stress on Emotional Reactivity and Resilience using Face2Face™ emotional analysis systems.
─ Interpersonal Emotion Lab with Dr. Nathaniel Herr
Proof-of-Concept Clinical Study with Boston VA Healthcare System (Behavioral Science Division)
Starting June 2018, a study in which we collect data from two groups of 25 subjects: one identified as having PTSD and the other PTSD-free, in order to establish the relationship between the presence of PTSD and evidence of involuntary emotional self-regulation in response to a set of 100 stimulus pictures with established degrees of emotional valance and arousal. This study will include a split-half design to explore if the subjects' levels of PTSD not only predict their reactivity to the stimulus pictures but their reactivity to the stimulus pictures will predict the subject's levels of PTSD.
─ Dr. Brian Marx, VA Boston
Proof-of-Concept Clinical Trial with Carrier Clinic, Belle Mead, NJ
Starting May 2018, a Proof-of-concept study of with 60 patients in early recovery from substance abuse. Clinician-facilitated sessions will be conducted in-person and by telehealth, using Facial Microexpressions of Emotion (FMEEs) as the clinical tool to impact measure the incidence of relapse. The study will be conducted under the auspices of a leading academic institution, Rutgers University. Upon completion, Carrier Clinic will initiate a larger study with 300-500 private practice patients. Carrier Clinic is the largest Mental Health facility in New Jersey.
─ Donald Parker, Carrier Clinic President & CEO
The American Psychiatric Association (APA) has scheduled a poster session on Face2Face™ at their 2018 Annual Convention held in the Javits Center (NYC) on May 7th (Poster #3591).
Committed to advancing mental healthcare
Founder, CEO, & Chairman
Mr. Kilmer is the founder of Future Life and is dedicated to providing low cost telehealth solutions towards improving quality of life to veterans, active-duty soldiers, and their families. He is responsible for overseeing transactions, marketing, management, operations, and finance. He has over twelve years of experience financing small businesses and private investments.
Dr. William d’Alelio
Chief Clinical Officer & Co-Founder
Dr. d’Alelio specializes in psychotherapy, Post-Traumatic Stress Disorder, and Program Development for Psychological Treatment. He has over 35 years of experience in Clinical Psychology. He received his PhD from University of Miami Coral Gables in 1983, with specialized training in PTSD Crisis Intervention at The Langley Porter Neuropsychiatric Institute of The University of California.
Director of Software Development
Formerly: SAIC, US Army
Mr. Ramsey is responsible for development of the Face2Face™ microexpression analytics platform. His professional expertise are cloud services, web & mobile applications, and desktop applications development. Mr. Ramsey provides technical, business, and intellectual property consulting. He earned a BS at Georgia Tech and MS in Computer Science at Frostburg State.
Samuel L Waltz Jr.
Sam Waltz Strategic Capital & Business Counsel
Chief Operating Officer
A Vietnam-era veteran of US Army Counter-Intelligence, Mr. Waltz is a global professional services consultant providing Strategic Business Counsel, Strategic Capital Services, and C-Level Executive Counsel. Mr. Waltz is working with Future Life to secure working capital. He earned his BS and MS in Journalism and Communications at the University of Illinois at Urbana-Champaign.
Vandyck Churchill, Ltd.
Chief Financial Officer
Mr. Brechter is a seasoned financial services executive, with extensive product development, strategic consulting and entrepreneurial experience. Bob is also known as the developer of the original Visa Gold card at Merrill Lynch and as an executive with the credit card company MBNA America. His BA in economics is from St. Lawrence University. His MBA in finance, marketing and international business is from Columbia University.
The Concierge, Inc.
Chief of Business Development & Sales Officer
Mr. Bradus has served as the head of quanitative analysis at Pfizer. He was in charge of sales and marketing analytics at Schering-Plough, and involved in the business development and successful launch of Dendrite in the US. He earned a B.A. from Brooklyn College, MBA from Baruch College, and APC from St. Johns University.
CME Acuity Rx, LLC
Chief Marketing Officer
Mr. Rothman has over 30 years of experience in the healthcare industry. He has successful track record in the development and marketing of new pharmaceuticals. He holds a BA in Chemistry from Hofstra University, MS in Organic Chemistry from NYU, and MBA in Marketing from Seton Hall University.
In Memory of John Mayhugh
Community Outreach Specialist
John Mayhugh had a strong background within the Washington, D.C. community.
His networking expertise provided Future Life with strong local and regional networks for outreach.
FutureLife.US supports the John P. Mayhugh Foundation.
Board of Directors
Chairman of the Board
Chief Executive Officer
Dr. William d’Alelio
Chief Clinical Officer
Co-founder of Future Life
Director of Veterans Affairs & Operations
Founder, CEO & President:
Mindful Memorial Day Foundation
Board of Advisors
Our advisors provide invaluable expertise in the areas of psychology, business management, government contracting, and marketing.
Dr. DAVID MATSUMOTO
Emotional Recognition Advisor
Mr. Matsumoto is the President of Humintell and foremost leader of research and education of micro expression and emotion analysis. Dr. Matsumoto provides experience in facial emotional recognition and its relation to algorithm development.
Mr. Gureff is an attorney specializing in technology transactions and intellectual property. He provides strategic counseling for intellectual property assets as well as structuring and negotiating technology transactions, joint ventures, and agreements.
FDA Regulatory Consultant Advisor
Sandi provides experience in regulatory affairs and strategic development for successful negotiations with health authorities. Sandi is an expert in Drug Development, Business Management and Marketing, External Affairs and Ally Development, Expanded Access, and Managed Access programs globally.
Dr. Paul Heinzelmann MD, MPH
Physician and Healthcare Entrepreneur. Dr. Heinzelmann works at Massachusetts General Hospital. He is an invaluable resource with regard to the telemedicine industry. He started RemoteCare Solution LLC in 2007. Graduate of Harvard University School of Public Health. Dr. Heinzelmann will assist in providing a greater understanding of the current state of telemedicine.
JORGE FRANCESCHI MSH, CCRC, RDN
CNS Trials Advisor
Mr. Franceschi has been involved in psychiatric clinical trials for over 17 years . During that time he has had roles in operations, clinical, business development, finances, and market intelligence for Phase I-IV research. He is a graduate of the University of Florida and University of North Florida.
info @ futurelife.us